1. Home
  2. HHH vs CRNX Comparison

HHH vs CRNX Comparison

Compare HHH & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Howard Hughes Holdings Inc.

HHH

Howard Hughes Holdings Inc.

HOLD

Current Price

$61.38

Market Cap

3.7B

Sector

Real Estate

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$35.44

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HHH
CRNX
Founded
2010
2008
Country
United States
United States
Employees
500
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.9B
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
HHH
CRNX
Price
$61.38
$35.44
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$90.00
$74.78
AVG Volume (30 Days)
543.2K
903.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.21
N/A
Revenue
$1,474,892,000.00
$1,039,000.00
Revenue This Year
$14.04
$722.66
Revenue Next Year
N/A
$183.79
P/E Ratio
$28.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.41
$24.10
52 Week High
$91.07
$57.99

Technical Indicators

Market Signals
Indicator
HHH
CRNX
Relative Strength Index (RSI) 24.66 26.12
Support Level N/A $33.23
Resistance Level $71.26 $37.23
Average True Range (ATR) 1.68 1.50
MACD -0.31 -0.01
Stochastic Oscillator 0.11 3.41

Price Performance

Historical Comparison
HHH
CRNX

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: